Research Article

Promising Neutrophil-Associated Biomarkers in Lung Diseases of Patients with Antisynthetase Syndrome and Dermatomyositis

Lei Liu,1 Jundi Wang,2 Peiyu Zhang,1 Wenjia Sun,1 Xiuliang Zhu,3 Xiujuan Sun,3 Jing Xue,1 and Huaxiang Wu1

1Department of Rheumatology, The Second Hospital Affiliated to Zhejiang University, College of Medicine, China
2Department of Rheumatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, China
3Department of Radiology, The Second Hospital Affiliated to Zhejiang University, College of Medicine, China

Correspondence should be addressed to Jing Xue; jingxue@zju.edu.cn and Huaxiang Wu; wuhx8855@zju.edu.cn

Received 27 February 2022; Revised 1 July 2022; Accepted 30 August 2022; Published 26 September 2022

Copyright © 2022 Lei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. Antisynthetase syndrome (ASS) and dermatomyositis (DM) are serious autoimmune diseases, with lungs being the most frequently involved organ and sometimes fatal. This study is aimed at clarifying the role of neutrophil-associated biological markers in suggesting ASS and DM-associated respiratory infections and interstitial lung diseases. Methods. We carried out a retrospective review of the medical records of 46 cases of ASS and DM diagnosed at the Second Hospital of Zhejiang University College of Medicine, between January 2017 and December 2020. Serum myeloperoxidase (MPO), neutrophil elastase (NE), α1 anti-trypsin (AAT), and interleukin-6 (IL-6) were also detected. Results. Gottron’s sign is characteristic of dermatomyositis, while polyarthritis is more characteristic of ASS. Pulmonary function is worse in ASS than in DM patients. Patients with ASS and DM had abnormal lymphocyte and neutrophil counts compared to healthy subjects, but not in relation to lung function and rapid progression of interstitial lung disease (RP-ILD). Elevated serum NE, MPO, and IL-6 levels are suggestive of respiratory infections, whereas decreased circulating IL-6 is predictive of RP-ILD. Conclusion. Our study identified the neutrophil-associated biomarkers MPO, NE, and IL-6 as promising indicators with different suggestive roles in respiratory infections and interstitial lung diseases in patients with ASS and DM.

1. Introduction

Idiopathic inflammatory myopathy (IIM) is a rare group of heterogeneous autoimmune diseases characterized by symmetric proximal muscle weakness and myositis-specific or associated autoantibodies, with extramuscular manifestations, and usually with high morbidity and mortality [1]. Lung involvement is the most common cause of death, especially in patients with ASS and DM [2]. The lack of effective and convenient indicators for monitoring lung diseases is an important factor in the poor prognosis of this group of patients. Although a number of predictive models have been reported [3–5], they often include indicators such as pulmonary imaging changes or lung function that are not easily reproducible in a short period of time, and the pulmonary progress associated with ASS and DM are often rapid. Therefore, it is still necessary to explore novel biomarkers that can predict the patient’s lung involvement. In particular, biomarkers for respiratory infections, RP-ILD, and early warning of lung function decline in patients are of great importance. Neutrophils are important innate immune cells; several studies have explored the pathogenesis of neutrophils in IIM. He and colleagues reported that acute and subacute interstitial lung diseases of DM patients group had a significantly higher proportion of neutrophils than the chronic group [6]. Very late antigen-4 expression on neutrophils might be useful for detecting the severity of lung diseases in patients with DM [7]. In addition, other specific biological forms or associated factors of neutrophils, like neutrophil extracellular traps (NETs), may also play an important role in IIM. NETs containing human cathelicidin were reported to be increased in patients with IIM and active disease and correlate with proinflammatory cytokines [8]. Peripheral NET levels are associated with calcinosis and interleukin
American College of Rheumatology (ACR) classifica-
tion criteria for adult and juvenile idiopathic inflammatory myopa-thies and their major subgroups comprehensive [13]. Since this study mainly focuses on IIM-related lung diseases and we have the data of myositis-specific antibodies of all enrolled patients, we combined patients with ADM and DM as DM for further study according to the new classification system [14]. Patients who met Connor’s Criteria were diagnosed as ASS and excluded from DM [15]. Data of the healthy people (healthy control, HC, \( n = 46 \)) were from the Health Examination Center of the Second Affiliated Hospital of Zhejiang University College of Medicine. The Medical Ethics Committee of the Second Affiliated Hospital of Zhejiang University, College of Medicine, approved this study (no. 2017-113). The informed consents of patients were obtained.

2.2. Data Collection. We reviewed the electronic medical records of all included IIM patients and collated the basic information, clinical manifestations, treatment, laboratory results, and radiological findings. Two experienced radiologists assessed chest high-resolution computer tomography (HRCT) images. Interstitial lung disease was mainly judged according to the clinical presentation of the patient and the chest HRCT. Diagnosis of respiratory infections was based on a combination of clinical manifestations, such as cough, sputum, and/or fever, laboratory investigations, and chest HRCT. The definition of RP-ILD is progressive dyspnea occurring within one month after the onset of respiratory symptoms and/or new interstitial abnormalities on chest radiography [3, 16]. Laboratory results including myositis-specific or associated autoantibodies and pulmonary function were obtained from the hospital’s electronic medical record system.

2.3. MPO and NE Assessment. MPO and NE originating from NETs are in the form of MPO:DNA complex and NE:DNA complex in the circulation. Therefore, MPO:DNA complex and NE:DNA complex (abbreviated as MPO and NE in the paper) were detected in this study.

2.4. Human MPO:DNA Complexes. Human MPO:DNA complexes were detected as previously reported [17]. High binding 96-well ELISA microplates were incubated overnight at 4°C with mouse anti-human MPO (clone 4A4; AbD Serotec) in coating buffer from the Cell Death Detection ELISA kit (cat# 11544675001; Roche). The Cell Death Detection ELISA kit is for determination of cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) after induced cell death. We take the coating buffer and DNA-POD for detecting DNA part of MPO:DNA and NE:DNA. After blocking with 1% BSA (cat# A7906; Sigma) in PBS, the plates were incubated overnight at 4°C with 10% human plasma in blocking buffer and washed, and anti-DNA-POD (clone MCA-33; Roche) was added for 1.5 hours at room temperature. Following incubation, TMB substrate (cat# T0440; Sigma) was added, and absorbance was measured at 450 nm after addition of stop reagent (cat# S5814; Sigma).

2.5. Human Neutrophil Elastase (NE):DNA Complexes. Human NE:DNA complexes were detected as previously reported [17]. High binding 96-well ELISA microplates were incubated overnight at 4°C with rabbit anti-human HNE6 (cat# 481001; Calbiochem) in PBS. After blocking, the plates were incubated overnight with 10% human plasma in blocking buffer, washed, and incubated for 1 hour at room temperature with mouse anti-dsDNA mAb (clone 16-13; EMD Millipore), followed by anti-mouse IgG-HRP conjugate (cat#1706516; BioRad, Hercules, CA). Procedure was completed as for MPO:DNA complexes.

2.6. AAT and IL-6 Assessment. A human AAT ELISA kit was purchased from BOSTER (cat# EK1634) and was used to measure the levels of serum AAT. The detection range of the ELISA kit was 1.56 ng/mL-100 ng/mL. A human IL-6 kit was purchased from Invitrogen (cat# BMS213-2) and was used to measure the levels of serum IL-6. The detection range of the ELISA kit was 1.56 pg/mL-100 pg/mL. All assays were performed according to the manufacturer’s recommendations. Cytokine concentrations were determined from standard concentrations plotted to create a standard curve.

2.7. Statistical Analysis. GraphPad Prism 8.0.1 (GraphPad Software, La Jolla, CA) was used for statistical analyses. Continuous variables are presented as the mean (S.D.) for a normal distribution or the median (interquartile range 25th–75th percentile) for a nonnormal distribution. Categorical variables are presented as frequencies. An independent sample t-test was used for pairwise comparison between groups of continuous variables with normal distribution and equal variance. The Wilcoxon rank-sum test was performed to analyse continuous data with a nonnormal distribution. Categorical variables were tested with a chi-square test. A \( P \) value < 0.05 was considered statistically significant.
significant. Of all the 16 patients with respiratory infections, seven patients had a previous diagnosis of IIM, all on glucocorticoid therapy, one in combination with mycophenolate mofetil and two in combination with cyclophosphamide. Of all the 16 patients with RP-ILD, five were thought to suffer respiratory infections. Other clinical characteristics, myalgia, muscle weakness, mechanic’s hands, and Raynaud phenomenon showed no significant differences.

3.2. Laboratory Data of the ASS and DM Patients. Compared with the normal reference values, most of the IIM patients had only mild to moderate elevation of creatine kinase (CK, 66.5 (26.0, 344.5)) and erythrocyte sedimentation rate (ESR, 24.0 (14.0, 36.0)), while most patients had normal C-reactive protein (CRP, 6.7 (4.7, 10.1)) levels (see Table 2). There was also no significant difference between the above indicators in ASS and DM patients. Most patients had mildly elevated lactate dehydrogenase (LDH, 293.5 (235.0, 448.0)) levels above the upper limit of normal reference values. The number of lymphocytes was significantly lower in DM patients than in ASS patients, while the number of white blood cells (WBC) and neutrophils did not differ significantly. In pulmonary function tests, both forced vital capacity (FVC) %, which reflects pulmonary restrictive ventilation dysfunction, and diffusing capacity of the lung for carbon monoxide (DLCO) %, which reflects diffusion function, were significantly lower in ASS patients than in DM patients. Data on myositis-specific antibodies were available for all IIM patients in our enrollment, and myositis-specific antibody types were abundant and representative of the disease groups in which they were located. Among them, the most frequent patients in the ASS group were with the anti-Jo-1 antibody, while in the DM group was the anti-MDA5 antibody, and notably, 26 of all 46 patients had a combination of the anti-Ro-52 antibody.

3.3. WBC, Lymphocytes, and Neutrophils in IIM Patients and Relationship with Lung Diseases. Compared to healthy controls (HC), patients with IIM had significantly higher WBC counts (P = 0.023) and neutrophil counts (P < 0.0001), but lower lymphocyte counts (P < 0.0001) (see Figure 1(a)). When subdivided, we found that ASS patients had higher WBC counts than healthy controls (P < 0.001), while DM patients had significantly lower lymphocyte counts compared to both ASS patients (P = 0.030) and healthy controls (P < 0.0001). Both ASS patients (P < 0.0001) and DM patients (P = 0.008) had higher neutrophil counts than healthy controls (see Figure 1(b)). The above immune cells were significantly different between IIM and healthy controls. However, when we performed correlation analysis with FVC% and DLCO%, indicators of lung function, there seemed to be no correlation between WBC, lymphocytes, and neutrophils and FVC% and DLCO% (see Figures 1(c) and 1(d) and Supplementary Figure 1). In addition, when the cell counts of RP-ILD patients (n = 16) were compared

### Table 1: Demographic and clinical characteristics of the ASS and DM patients.

| Variables                  | All          | ASS          | DM           | P value |
|----------------------------|--------------|--------------|--------------|---------|
| Numbers, n (%)             | 46 (100)     | 20 (43.5)    | 26 (56.5)    |         |
| Age, year                  | 57.3 ± 10.9  | 61.1 ± 7.9   | 57.3 ± 12.2  | 0.061   |
| Female, n (%)              | 33 (71.7)    | 17 (85.0)    | 16 (61.5)    | 0.08    |
| Smoke, n (%)               | 9 (19.6)     | 3 (15.0)     | 6 (23.1)     | 0.494   |
| Fever, n (%)               | 10 (21.7)    | 6 (30.0)     | 4 (15.4)     | 0.234   |
| Myalgia, n (%)             | 11 (23.9)    | 4 (20.0)     | 7 (26.9)     | 0.585   |
| Muscle weakness, n (%)     | 23 (50.0)    | 8 (40.0)     | 15 (57.7)    | 0.234   |
| Gottron’s sign, n (%)      | 33 (71.7)    | 9 (45.0)     | 24 (92.3)    | <0.0001*** |
| Mechanical’s hands, n (%)  | 12 (26.1)    | 7 (35.0)     | 5 (19.2)     | 0.227   |
| Raynaud phenomenon, n (%)  | 7 (15.2)     | 5 (25.0)     | 2 (7.7)      | 0.105   |
| Polyarthritis, n (%)       | 17 (37.0)    | 11 (55.0)    | 6 (23.1)     | 0.026*  |
| Respiratory infection, n (%)| 13 (28.3)    | 6 (30.0)     | 7 (26.9)     | 0.818   |
| Interstitial lung disease, n (%) | 33 (71.7) | 16 (80.0) | 17 (65.4) | 0.275 |
| RP-ILD, n (%)              | 16 (34.8)    | 7 (35.0)     | 9 (34.6)     | 0.978   |

Values are mean ± SD n (%) unless specified otherwise. *P < 0.05 for comparison between ASS group vs. DM group using a χ² test, Gottron’s sign, and polyarthritis.
Table 2: Laboratory variants of the ASS and DM patients.

| Variables          | All    | ASS   | DM    | P value |
|--------------------|--------|-------|-------|---------|
| CK (U/L)           | 66.5   | 63.5  | 142   | 0.209   |
| (26.0, 383.8)      | (25.3, 344.5) | (33, 623.3) |         |
| ESR (mm/h)         | 24.0   | 21.5  | 28    | 0.578   |
| (13.5, 36.3)       | (15, 31.5) | (9.5, 37.3) |         |
| CRP (mg/L)         | 6.7    | 8.1   | 6.4   | 0.324   |
| (4.7, 10.6)        | (4.7, 10) | (4.5, 11.3) |         |
| LDH (U/L)          | 293.5  | 285.0 | 322.0 | 0.333   |
| (232.8, 471.3)     | (224.5, 337.5) | (258.0, 549.0) |         |
| WBC (×10⁹/L)       | 7.1    | 7.9   | 6.1   | 0.073   |
| (5.2, 9.1)         | (5.9, 9.4) | (4.4, 8.4) |         |
| Lymphocyte (×10⁹/L)| 0.9    | 1.2   | 0.6   | 0.03*   |
| (0.5, 1.3)         | (0.9, 1.5) | (0.4, 1.1) |      |
| Neutrophil (×10⁹/L)| 5.3    | 6.2   | 4.6   | 0.077   |
| (3.6, 7.2)         | (4.2, 8.1) | (3.2, 6) |         |
| FVC (%)            | 81.2   | 74.3  | 84    | 0.164   |
| (66.6, 92.2)       | (64.8, 83.9) | (66.6, 105) |        |
| DLCO (%)           | 71.4   | 48.3  | 81.8  | <0.0001 |
| (48.9, 83.8)       | (35.5, 58.4) | (77, 86.3) |         |
| Disease duration (month) | 3.0   | 3     | 3     | 0.401   |
| (2.4, 6.0)         | (2.1, 6) | (2, 8.4) |         |

Myositis antibodies, n

- Anti-Jo-1: 13
- Anti-O: 2
- Anti-EJ: 4
- Anti-PL-7: 1
- Anti-PL-12: 3
- Anti-MDA5: 12
- Anti-NXP-2: 3
- Anti-TIF-1γ: 4
- Anti-Mi-2: 1
- Anti-Ro-52 (alone): 4
- Anti-Ro-52 (with other antibodies): 26
- Negative: 2

Values are mean ± SDn (%) or the quartile method. *P < 0.05 for comparison between ASS group vs. DM group using an independent sample t test or the Wilcoxon rank-sum test.

with those of other ILD patients (n = 17), we did not find any difference between the two groups (Figure 1(e)). It suggested that WBC, lymphocyte, and neutrophil counts, despite the differences between IIM and healthy controls, do not seem to be significantly suggestive of IIM-related lung diseases. Similarly, there was no clear relationship between the presence or absence of respiratory infections and the number of WBC, neutrophils, and lymphocytes in IIM patients (Figure 1(f)).

3.4. Decreased IL-6 Predicted RP-ILD of IIM Patients. Since neutrophil count did not appear to be directly related to lung diseases, we investigated some biomarkers associated with neutrophils. NE (P = 0.226) and MPO (P = 0.067) did not differ significantly between patients in the RP-ILD and non-RP-ILD groups; however, IL-6 (P = 0.0002) level was significantly lower in patients in the RP-ILD group (see Figures 2(a), 2(c), and 2(d)). There was also no significant difference in AAT between the two groups in the presence or absence of RP-ILD (P = 0.138) (see Figure 2(b)). ROC curves and their cut off values were also calculated. ROC analysis showed the AUC values of IL-6 (Figure 2(e)) at 0.884 (95% CI 0.762–1.000, P = 0.0002) with a cut off value 3.7 pg/mL, indicating decreased IL-6 to predict patients with RP-ILD.

3.5. MPO, NE, and IL-6 in Respiratory Infections of IIM Patients. MPO (P = 0.049), NE (P = 0.049), and IL-6 (P = 0.014) were significantly higher in ASS and DM patients with respiratory infections compared to patients without respiratory infections (see Figures 3(a), 3(c), and 3(e)). We calculated ROC curves and their cutoff values. ROC analysis showed the AUC values of MPO (Figure 3(b)) at 0.692 (95% CI 0.523–0.861, P = 0.044); NE (Figure 3(d)) at 0.692 (95% CI 0.525–0.859, P = 0.044); and AUC values of IL-6 (Figure 3(f)) at 0.720 (95% CI 0.561–0.880, P = 0.021). From the ROC curves, cut off values for MPO, NE, and IL-6 were 5.9 ng/mL, 15.95 ng/mL, and 2.71 pg/mL, respectively. Above results indicated a strong performance of MPO, NE, and IL-6 to identify patients with possible respiratory infections. There was no significant difference between AAT (P = 0.704) in patients with and without respiratory system infections (see Figure 3(g)).

3.6. AAT Might Be a Predictor of Poor Lung Function. We found a negative correlation of AAT with FVC (r = −0.034, P = 0.025), Figure 4(a). But no correlation was seen in MPO, NE, or IL-6 (see Supplement Figure 2). However, AAT showed no correlation with FVC% (r = −0.052, P = 0.896) or DLCO% (r = −0.323, P = 0.366) (see Figures 4(b) and 4(c)). The correlation analysis of other indicators could be seen in Supplementary Figure 2.
4. Discussion

IIM is a serious autoimmune disease involving multiple organs, of which vascular inflammatory lesions of the skin, severe muscle involvement, and rapidly progressive interstitial lung disease are the most common reasons for hospitalization, and even death [18]. At the same time, treatment for active autoimmune diseases, including IIM, always depends on high doses of glucocorticoids and immunosuppressive agents. The therapy often exacerbates...
the patient’s immunosuppressed state and brings infections, especially respiratory infections. Both progression of the IIM and respiratory infections may further contribute to RP-ILD. Therefore, early recognition and identification of respiratory infections and RP-ILD in IIM patients is crucial for rheumatologists, yet it is a major challenge to determine from imaging and common laboratory data.

A growing number of studies have identified biomarkers associated with IIM, particularly interstitial lung diseases. Bae and colleagues found the arylesterase and lactonase activities of paraoxonase-1 are significantly impaired in IIM patients and inversely associated with IIM disease activity and the presence of severe ILD [19]. Progranulin was also reported to be correlated with RP-ILD in anti-MDA5 antibody-positive DM patients [20]. Lian et al. developed a FLAIR Model with the metrics, ferritin, LDH, titer of anti-MDA5 antibody, chest HRCT score, and RP-ILD, which can predict the mortality risk of patients with anti-MDA5 antibody-positive DM [3]. As mentioned above, neutrophils, NETs, and their associated cytokines may all be involved in

![Figure 2: Decreased IL-6 predicted RP-ILD of IIM patients. (a–c) NE (P = 0.226), AAT (P = 0.138), and MPO (P = 0.067) did not differ significantly between patients in the RP-ILD and non-RP-ILD groups. (d) IL-6 (P = 0.0002) level was significantly lower in patients in the RP-ILD group. The results of the IL-6 assay ranged from 0.98 to 7.74 pg/mL (the second lowest was 1.31 pg/mL). (e) ROC analysis showed that the AUC values of IL-6 at 0.884 (95% CI 0.762–1.000, P = 0.0002).]
Figure 3: MPO, NE, and IL-6 in respiratory infections of IIM patients. In the ASS and DM patients with respiratory infections compared to patients without respiratory infections, MPO (a) ($P = 0.049$), NE (c) ($P = 0.049$), and IL-6 (e) ($P = 0.014$) were significantly higher. ROC analysis showed that the AUC values of MPO (b) at 0.692 (95% CI 0.523–0.861, $P = 0.044$), NE (d) at 0.692 (95% CI 0.525–0.859, $P = 0.044$), and AUC values of IL-6 (f) at 0.720 (95% CI 0.561–0.880, $P = 0.021$). (g) AAT was not significantly different in the two groups of patients.
IIM-associated ILD, as well as being indicators of respiratory infections. Therefore, we investigated the role of these neutrophil-associated biomarkers in IIM-associated lung diseases, including respiratory infections, the development of RP-ILD, and lung function.

Although the concept of ASS has long been proposed, ASS has been considered part of DM until the new classification system in 2018. In the first part of our study, we summarize and compare the clinical and laboratory characteristics of patients with ASS and DM in this cohort. The general clinical features of IIM, including fever, myalgia, and muscle weakness, were present in both our patient groups, but there was no particular difference between the ASS and DM groups. The proportion of ASS patients with mechanic’s hand and Raynaud phenomenon was higher than that of DM, but not statistically different. The most characteristic manifestations were Gottron’s sign for DM and polyarthritis for ASS. Therefore, in addition to the myositis-specific and associated antibodies, Gottron’s sign and polyarthritis provide us with a good means of differentiation when distinguishing between ASS and DM in clinical practice. The incidence of respiratory infections and RP-ILD was about 30% in both ASS and DM groups, with no significant difference. Although interstitial lung disease in DM is currently considered a major challenge for rheumatologists, the prevalence of ILD in ASS is indeed very high, up to 80%, and the incidence of RP-ILD is not lower than in DM.

CK, ESR, and CRP were essentially normal or mildly elevated in all patients in this cohort, and there were no significant differences between the ASS and DM groups. LDH was elevated in most patients, but there were no significant differences between the two groups. Lymphocytes were significantly lower in patients with DM, which has been discussed in previous literatures [21, 22]; however, WBC and neutrophils did not differ significantly. Interestingly, despite the seemingly more aggressive lung diseases in DM, pulmonary function tests suggested that both FVC% and DLCO% were significantly lower in patients in the ASS group than in those in the DM group in this cohort. Previous studies have identified poor lung function in patients with ASS and improvement of lung function after treatment [23–25]. Nevertheless, comparative studies of the differences in lung function between patients with ASS and those with DM are more lacking, which has led rheumatologists to pay more attention to lung involvement in ASS. All patients in the cohort had results for myositis-specific antibodies. Patients with ASS had various myositis-specific or associated antibodies, most often the anti-Jo-1 antibody, and the anti-MDA5 antibody was the most common antibody in DM patients.

When we introduced healthy controls for comparison, although the WBC, lymphocyte, and neutrophil counts were essentially normal or mildly elevated in patients with IIM, both the WBC and neutrophil counts were elevated, and the lymphocyte count was decreased compared to healthy controls. Subgroup analysis revealed that lymphocyte counts were lower in both ASS and DM patients than in healthy controls, while neutrophil counts were higher. These differences in cell counts suggest that lymphocytes and neutrophils are

**Figure 4:** AAT might not be a good predictor of poor lung function. (a) There was a negative correlation between AAT and FVC (\(r = -0.034, P = 0.025\)). (b) No correlation of AAT with FVC% (\(r = -0.052, P = 0.896\)). (c) No correlation of AAT with DLCO% (\(r = -0.323, P = 0.366\)).
involved in IIM pathogenesis; however, their relationship with IIM lung disease still needs further discussion. Follow-up analyses revealed that none of the above cell counts was significantly suggestive of lung function, respiratory infections, or RP-ILD. Therefore, it is particularly important to explore the relevant biomarkers.

NETs is a newly discovered way of neutrophil death. Chromatin decondensation by citrullinated histone 3 (citH3) and granule proteins, including MPO and NE, is involved in the breakdown of membranaceous structures, allowing for a mixture of nuclear and cytoplasmic contents. Finally, cell-free DNA (cfDNA) and granule proteins are released as NETs [26]. Several studies have indicated that circulating NETs are potential biomarkers in many rheumatic diseases [27–29]. Circulating NETs were reported to be associated with higher levels of anti-MDA5 antibody and skin disease activity [30]. Low-density granulocytes and NETs containing LL-37 were also increased in patients with IIM and active disease and correlate with proinflammatory cytokines [8]. IIM NETs decreased the viability of myotubes in a citrullinized histone-dependent manner. Dysregulated neutrophil pathways may play pathogenic roles in IIM through their ability to directly injure muscle cells and other affected tissues [30]. There is a lack of research on the relationship between NETs and IIM-ILD, especially whether it could suggest RP-ILD. However, no significant differences in circulating NE and DNA were seen in our cohort of RP-ILD patients compared to those who did not present with RP-ILD. This suggests that although NETs may be involved in the pathogenesis of IIM, particularly in muscle and skin lesions, circulating NETs do not serve as important markers of RP-ILD pathogenesis. What surprised us, however, were the results for IL-6. Our data suggest that IL-6 was lower in IIM-ILD patients who did not present RP-ILD. There have been many studies on the relationship between IL-6 and IIM; serum IL-6 and immune cell expressions of IL-6 were increased in IIM patients than healthy people [31, 32]. Therefore, instead of simply comparing IL-6 with healthy individuals, we specifically studied IL-6 in RP-ILD. Studies have been found successful tocilizumab treatment of RP-ILD in anti-MDA5 antibody-positive DM patients [33]; we have also successfully treated an NXP-2 antibody-positive DM patient with tocilizumab [34]. The levels of serum IL-6 were reported to be higher in the RP-ILD subset than in the non-ILD subset or the chronic ILD subset in IIM, but there was no significance [35]. Our data suggest that IL-6 levels were significantly lower in patients with RP-ILD. This is contrary to the persistent perception that RP-ILD in IIM is closely associated with inflammatory cytokine storms like severe COVID-19 [36, 37], so it is cautious to assume that high circulating IL-6 was not a hallmark of RP-ILD, much less simply an indication for the utilization of tocilizumab, which is important for clinical practice. In addition, since pulmonary infection is one of the important triggers of RP-ILD, and IL-6 is significantly elevated in patients with respiratory infections, it is likely that some of the studies did not distinguish infection from RP-ILD well and therefore concluded that IL-6 is elevated in patients with RP-ILD.

Respiratory infections in IIM patients are also a frequent clinical situation and often need to be differentiated from ILD and even RP-ILD. Our study found that circulating NE, MPO, and IL-6 were significantly elevated in both ASS and DM patients with comorbid respiratory infections and have good diagnostic value. NETs and IL-6 have been studied extensively in pulmonary infections including COVID-19 [38, 39], and the findings are more consistent with the results of our study in concluding that circulating NETs and IL-6 could suggest respiratory infections. In particular, we have found that circulating IL-6 was decreased in patients with RP-ILD and significantly increased in respiratory infections. Although respiratory infections are an important predisposing factor for RP-ILD, the results of this study tell us very clearly that elevated IL-6 suggested infection rather than RP-ILD, and that the combined NE and MPO assays provide better clarity. This is of great importance for treatment decisions.

AAT is an important inhibitor of the protease, neutrophil elastase, which results in the breakdown of lung matrix elastin. And AAT deficiency (AATD) is a common reason for emphysema and thought to be an important factor in maintaining structural stability of the lung [40]. Our results found no clear implication of AAT for either RP-ILD or respiratory infections, while AAT showed a negative correlation with FVC in the study of lung function. However, when compared to FVC%, there was no significant correlation. We have a hypothesis that FVC declines reflect changes in lung structure, and AAT is important for maintaining the stability of lung structure, and the elevation of AAT may be the body's compensation for lung structure especially related to lung NE activation. Nevertheless, the comparison of FVC% is more practically meaningful than the absolute value of FVC, so AAT also does not seem to be a good predictor of lung function decline as a treatment. Perhaps expanding the sample size could make this conclusion clearer.

All in all, we have demonstrated that elevated IL-6 in serum is not a predictor of RP-ILD, elevated circulating NE, MPO, and IL-6 all suggest respiratory infections, and finally, AAT is an indicator of poor lung function in ASS and DM patients. Our observation is important, as it could provide information for better differentiating RP-ILD and respiratory infections. In addition, our study contributes to a more accurate understanding of the role of IL-6 in ASS and DM-related lung diseases. Elevated circulating IL-6 level does not imply the development of RP-ILD, but more likely represents respiratory infection, so it is inappropriate to apply IL-6 levels as an indication to initiate tocilizumab. Finally, elevated levels of circulating AAT, an important inhibitor of NE protease activity in lung tissue, predicted a decline in FVC, but it does not have a good predictive value for FVC% and therefore may not be a good predictor of lung function.

**Data Availability**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Additional Points

Key Messages. (1) Decrease in IL-6 levels is a prognostic indicator for the development of RP-ILD. (2) Elevated circulating NE, MPO, and IL-6 all suggest respiratory infections.

Ethical Approval

The Medical Ethics Committee of the Second Affiliated Hospital of Zhejiang University, College of Medicine, approved this study (no. 2017-113). All methods were performed in accordance with the relevant guidelines and regulations.

Consent

The informed consents of patients were obtained.

Conflicts of Interest

The authors have declared no competing interests.

Authors’ Contributions

LL and HW designed the experiments and wrote the manuscript. PZ was responsible for the enrollment of patients; WS and JW performed the experiments. LL and JX ran the statistical analysis of the data. XZ and XS assessed the HRCT of the patients. All authors reviewed and approved the final version of the manuscript. Lei Liu and Jundi Wang contributed equally to this study.

Acknowledgments

The authors would like to thank all subjects who participated in this study. National Natural Science Foundation of China, no. 81801597, supported this work.

Supplementary Materials

Supplementary Figure 1: in all the patients with IIM: (A, B) no correlations between WBC and FVC% and DLCO% were seen. (C, D) No correlations between lymphocytes and FVC% and DLCO% were seen. Supplementary Figure 2: in all the patients with IIM: (A–C) IL-6 did not correlate with FVC%, FVC, or DLCO, respectively. (D–F) MPO did not correlate with FVC%, FVC, or DLCO, respectively. (G–I) NE did not correlate with FVC%, FVC, or DLCO, respectively. (Supplementary Materials)

References

[1] L. Gupta, H. Muhammed, R. Naveen et al., "Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians," *Rheumatology International*, vol. 40, no. 12, pp. 2047–2055, 2020.

[2] A. L. Mammen, Y. Allenbach, W. Stenzel, O. Benveniste, and Group EtWS, "239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018," *Neuromuscular Disorders*, vol. 30, no. 1, pp. 70–92, 2020.

[3] X. Lian, J. Zou, Q. Guo et al., "Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model," *Chest*, vol. 158, no. 4, pp. 1535–1545, 2020.

[4] W. Wu, W. Xu, W. Sun et al., "Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study," *Rheumatology (Oxford, England)*, vol. 61, no. 1, pp. 230–239, 2022.

[5] Y. Li, Y. Li, Y. Wang et al., "A clinical risk model to predict rapidly progressive interstitial lung disease incidence in dermatomyositis," *Frontiers in medicine*, vol. 1, p. 1616, 2021.

[6] L. He, Y. Ge, S. Li et al., "Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease," *Rheumatology*, vol. 61, no. 1, pp. 345–354, 2021.

[7] M. Lin, C. Yang, X. Liu et al., "Increased levels of VCAM-1 in sera and VLA-4 expression on neutrophils in dermatomyositis with interstitial lung disease," *Immunological Investigations*, vol. 51, no. 4, pp. 1–13, 2022.

[8] J. Torres-Ruiz, D. A. Carrillo-Vázquez, A. Leal-Alanis et al., "Low-density granulocytes and neutrophil extracellular traps as biomarkers of disease activity in adult inflammatory myopathies," *Journal of Clinical Rheumatology*, vol. 28, no. 2, pp. e480–e487, 2022.

[9] B. Duvvuri, L. M. Pachman, G. Morgan et al., "Neutrophil extracellular traps in tissue and periphery in juvenile dermatomyositis," *Arthritis & Rheumatology*, vol. 72, no. 2, pp. 348–358, 2020.

[10] M. Zimmermann, F. B. Aguilera, M. Castellucci et al., "Chromatin remodelling and autocrine TNFα are required for optimal interleukin-6 expression in activated human neutrophils," *Nature Communications*, vol. 6, no. 1, p. 6061, 2015.

[11] P. Domingo, I. Mur, G. M. Mateo et al., "Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19," *Journal of the American Medical Association*, vol. 326, no. 6, pp. 499–518, 2021.

[12] S. C. Larsson, S. Burgess, and D. Gill, "Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia," *European Respiratory Journal*, vol. 57, no. 1, p. 2003545, 2021.

[13] I. E. Lundberg, A. Tjarnlund, M. Bottai, V. P. Werth, C. Pilkington, and M. Visser, "Repository.(2017). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups," *Arthritis & Rheumatology*, vol. 69, no. 12, pp. 2271–2282, 2017.

[14] K. Mariampillai, B. Granger, D. Amelin et al., "Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies," *JAMA Neurology*, vol. 75, no. 12, pp. 1528–1537, 2018.

[15] G. R. Connors, L. Christopher-Stine, C. V. Oddis, and S. K. Danoff, "Interstitial lung disease associated with the idiopathic inflammatory myopathies," *Chest*, vol. 138, no. 6, pp. 1464–1474, 2010.

[16] S. Sato, M. Hirakata, M. Kuwana et al., "Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis," *Arthritis and Rheumatism*, vol. 52, no. 5, pp. 1571–1576, 2005.
[17] C. Lood, L. P. Blanco, M. M. Purmalek et al., “Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease,” Nature Medicine, vol. 22, no. 2, pp. 146–153, 2016.

[18] J. C. Lega, Q. Reynaud, A. Belot, N. Fabien, I. Durieu, and V. Cottin, “Idiopathic inflammatory myopathies and the lung,” European Respiratory Review, vol. 24, no. 136, pp. 216–238, 2015.

[19] S. S. Bae, A. Shahbazian, J. Wang et al., “Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies,” Rheumatology, vol. 61, no. 6, pp. 2512–2523, 2022.

[20] L. Shanshan, Z. Yamei, Z. Ling, L. Xin, and W. Guochun, “Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody,” Clinical Rheumatology, vol. 41, no. 3, pp. 757–763, 2022.

[21] C. Franco, M. Gatto, L. Iaccarino, A. Ghirardello, and A. Doria, “Lymphocyte immunophenotyping in inflammatory myositis: a review,” Current Opinion in Rheumatology, vol. 33, no. 6, pp. 522–528, 2021.

[22] C. Li, M. Liang, H. Jiang et al., “The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study,” Rheumatology (Oxford, England), vol. 60, no. 5, pp. 2288–2295, 2021.

[23] P. Korsten, J. G. Rademacher, L. Riedel et al., “Antisynthetase syndrome-associated interstitial lung disease: monitoring of immunosuppressive treatment effects by chest computed tomography,” Frontiers in medicine, vol. 7, no. 7, article 609595, 2021.

[24] G. Dei, P. Rebora, M. Catalano et al., “Functional progression in patients with interstitial lung disease resulted positive to antisynthetase antibodies: a multicenter, retrospective analysis,” Journal of Clinical Medicine, vol. 9, no. 9, p. 3033, 2020.

[25] J. A. Huapaya, L. Silhan, I. Pinal-Fernandez et al., “Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease,” Chest, vol. 156, no. 5, pp. 896–906, 2019.

[26] V. Papayannopoulos, “Neutrophil extracellular traps in immunity and disease,” Nature Reviews. Immunology, vol. 18, no. 2, pp. 134–147, 2018.

[27] S. Moore, H. H. Juo, C. T. Nielsen, H. Tyden, A. A. Bengtsson, and C. Lood, “Role of neutrophil extracellular traps regarding patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus,” The Journal of Rheumatology, vol. 47, no. 11, pp. 1652–1660, 2020.

[28] M. Bruschi, A. Bonanni, A. Petretto et al., “Neutrophil extracellular traps profiles in patients with incident systemic lupus erythematosus and lupus nephritis,” The Journal of Rheumatology, vol. 47, no. 3, pp. 377–386, 2020.

[29] W. Wang, W. Peng, and X. Ning, “Increased levels of neutrophil extracellular trap remnants in the serum of patients with rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 21, no. 2, pp. 415–421, 2018.

[30] N. Seto, J. J. Torres-Ruiz, C. Carmona-Rivera et al., “Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies,” Ici Insight, vol. 5, no. 3, 2020.

[31] Y. Lou, Y. Zheng, B. Fan et al., “Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease,” BMC Pulmonary Medicine, vol. 20, no. 1, p. 196, 2020.

[32] N. Seto, J. J. Torres-Ruiz, C. Carmona-Rivera et al., “Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies,” Rheumatology (Oxford, England), vol. 59, no. 1, pp. 194–204, 2019.

[33] X. Zhang, S. Zhou, C. Wu et al., “Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis,” Rheumatology (Oxford, England), vol. 60, no. 7, pp. e227–e228, 2021.

[34] Z. Lu, Y. Chen, J. Xue, and L. Liu, “NXP2-positive dermatomyositis complicated with refractory skin edema: successful treatment with tocilizumab,” Dermatologic Therapy, vol. 34, no. 1, article e14712, 2021.

[35] H. Kawasaki, T. Gono, Y. Kawaguchi et al., “IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis,” BioMed Research International, vol. 2014, Article ID 815245, 6 pages, 2014.

[36] J. Alijotas-Reig, E. Esteve-Valverde, C. Belizna et al., “Immuno- modulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review,” Autoimmunity reviews, vol. 19, no. 7, article 102569, 2020.

[37] O. Sanchez-Pernaute, F. I. Romero-Bueno, and A. Selva-O’Callaghan, ¿Por que elegir ciclosporina A como primera linea terapeutica para la neumonia causada por COVID-19?, Reumatología Clínica, vol. 17, no. 9, pp. 555–557, 2021.

[38] S. H. Twaddell, P. G. Gibson, C. Grainge, and K. J. Baines, “Parapneumonic effusions are characterized by elevated levels of neutrophil extracellular traps,” Chest, vol. 160, no. 5, pp. 1645–1655, 2021.

[39] J. Declercq, K. F. Van Damme, E. De Leeuw et al., “Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COVID-AID): a factorial, randomised, controlled trial,” The Lancet Respiratory Medicine, vol. 9, no. 12, pp. 1427–1438, 2021.

[40] V. Tejwani and J. K. Stoller, “The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency,” Therapeutic Advances in Chronic Disease, vol. 12, 2021.